Prior neoplasms and therapy in patients with tCMML
| Variable . | n (%) . |
|---|---|
| Median time from previous cancer to tCMML diagnosis, y (range) | 6.5 (0.1-24.4) |
| Prior neoplasms | |
| Prostate | 18 (25) |
| Lymphoid | 16 (23) |
| Breast | 10 (14) |
| Head and neck | 8 (11) |
| Colorectal | 8 (11) |
| Lung | 5 (7) |
| Ovarian | 3 (4) |
| Other | 7 (10) |
| Therapy | |
| RT only | 25 (35) |
| CT only | 22 (31) |
| CT and RT | 24 (34) |
| Type of chemotherapy | |
| Alkylating agents | 32 (45) |
| Mitotic inhibitors | 26 (37) |
| Antimetabolites | 25 (35) |
| Antitumor antibiotics | 17 (24) |
| Type II topoisomerase inhibitors | 7 (10) |
| Other | 2 (3) |
| Unknown | 8 (11) |
| Variable . | n (%) . |
|---|---|
| Median time from previous cancer to tCMML diagnosis, y (range) | 6.5 (0.1-24.4) |
| Prior neoplasms | |
| Prostate | 18 (25) |
| Lymphoid | 16 (23) |
| Breast | 10 (14) |
| Head and neck | 8 (11) |
| Colorectal | 8 (11) |
| Lung | 5 (7) |
| Ovarian | 3 (4) |
| Other | 7 (10) |
| Therapy | |
| RT only | 25 (35) |
| CT only | 22 (31) |
| CT and RT | 24 (34) |
| Type of chemotherapy | |
| Alkylating agents | 32 (45) |
| Mitotic inhibitors | 26 (37) |
| Antimetabolites | 25 (35) |
| Antitumor antibiotics | 17 (24) |
| Type II topoisomerase inhibitors | 7 (10) |
| Other | 2 (3) |
| Unknown | 8 (11) |
Data from n = 71 patients.
CT, chemotherapy; RT, radiotherapy.